This is a routine clinical milestone with no hard financial data. Monitor for actual patient enrollment data or financing updates, but no immediate catalyst for upside.
Price Chart
Executive Summary
Clearmind Medicine announced that the Johns Hopkins Medicine IRB has approved its Phase I/II trial of CMND-100 for Alcohol Use Disorder, allowing the company to proceed with Parts B and C. This is a routine clinical milestone for a micro-cap biotech with no financial data or revenue, and the stock has historically declined on similar neutral news.
Key Facts
- Johns Hopkins Medicine IRB approved Phase I/II trial of CMND-100 for Alcohol Use Disorder
- Approval permits Clearmind to proceed with Parts B and C of the multicenter study
- No financial terms, revenue, or guidance disclosed in the press release
- Clearmind is a clinical-stage biotech with no approved products or revenue
Financial Impact
No financial figures disclosed; pre-revenue clinical-stage company
Risk Factors
- No revenue or near-term commercialization path; cash burn risk
- Clinical trial failure or delay could be catastrophic for a single-asset micro-cap
- Historical pattern of negative stock reaction to neutral news
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3301074 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 6-K | $5.92 | awaiting T+60 | — | $5.95 (+0.47%) |
Oct 27, 2026 today | Press Release | $6.50 | awaiting T+60 | — | $5.95 (−8.50%) |
Oct 16, 2026 10d ago | 6-K | $6.00 | awaiting T+60 | — | $5.95 (+0.87%) |
Oct 13, 2026 14d ago | 6-K | $6.23 | awaiting T+60 | — | $5.95 (−4.53%) |
Oct 8, 2026 19d ago | 6-K | $6.60 | awaiting T+60 | — | $5.95 (−9.88%) |
Oct 7, 2026 20d ago | 6-K | $6.60 | awaiting T+60 | — | $5.95 (−9.88%) |
Sep 23, 2026 4w ago | 6-K | $0.8500 | awaiting T+60 | — | $5.95 (+599.72%) |
Sep 23, 2026 4w ago | Press Release | $0.8500 | awaiting T+60 | — | $5.95 (+599.72%) |
Sep 17, 2026 5w ago | Press Release | $6.86 | awaiting T+60 | — | $5.95 (−13.35%) |
Sep 14, 2026 6w ago | 6-K | $0.9440 | awaiting T+60 | — | $5.95 (+530.04%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers